Company intelligence / Profile preview

Wallace Laboratories

Ownership: Private
Development stage: Other

Overview

Wallace Laboratories (as part of the Wallace Group) produces a broad range of commercialized medicines for multiple therapeutic areas. Its parent group has over five decades’ presence in India and international markets. Flagship brands include Diovol (antacid), among others. No clinical-stage pipeline or investigational drugs are highlighted; business centers on established formulations for Indian and emerging markets.

Therapeutic areas: NeurologyWomen's HealthPulmonologyInfectious DiseasesDermatologyGastroenterologyCardiovascular
Modalities: Small moleculeBiologics
Industry: Biotech

Drug pipeline

4 assets

felbamate

Approved

3 more assets in the full pipeline.

Partnerships

Contract manufacturing for several reputed international pharmaceutical companies; specifics not disclosed publicly

Beyond the preview

Go deeper on Wallace Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wallace Laboratories.